These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 1813363)

  • 41. Maintenance therapy with interferon-alpha (IFN-alpha) versus IFN-alpha plus chemotherapy in multiple myeloma (MM). The Greek Myeloma Study Group.
    Zervas K; Pouli A; Perifanis V; Papanastasiou K; Chatziyianni M; Mitsouli C; Maniatis A
    Eur J Haematol; 1996 Aug; 57(2):142-8. PubMed ID: 8856091
    [TBL] [Abstract][Full Text] [Related]  

  • 42. M-2 protocol for melphalan-resistant and relapsing multiple myeloma.
    Cavo M; Galieni P; Tassi C; Gobbi M; Tura S
    Eur J Haematol; 1988 Feb; 40(2):168-73. PubMed ID: 3345830
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Multiple myeloma: the therapeutic options].
    Sánchez Fayos J; Prieto E; Roman A; Olavarria E
    An Med Interna; 1992 Feb; 9 Spec No():112-8. PubMed ID: 1550902
    [No Abstract]   [Full Text] [Related]  

  • 44. Melphalan-resistant multiple myeloma: results of treatment according to the M-2 protocol.
    Steinke B; Busch FW; Becherer C; Ostendorf P; Waller HD
    Cancer Chemother Pharmacol; 1985; 14(3):279-81. PubMed ID: 3838922
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Treatment of myeloma and and expected prognostic progress].
    Fermand JP
    Rev Prat; 1991 Dec; 41(25):2588-91. PubMed ID: 1687086
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Combination chemotherapy for multiple myeloma with BCNU, cyclophosphamide, vincristine, melphalan, and prednisone (M-2 protocol).
    Case DC; Sonneborn HL; Paul SD; Hayes DM; Dorsk BM; Carroll RJ; Bove L
    Oncology; 1985; 42(3):137-40. PubMed ID: 3858763
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Alpha-2a-interferon/melphalan/prednisone versus melphalan/prednisone in previously untreated patients with multiple myeloma.
    Montuoro A; De Rosa L; De Blasio A; Pacilli L; Petti N; De Laurenzi A
    Br J Haematol; 1990 Nov; 76(3):365-8. PubMed ID: 2261347
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Monoclonal gammapathy of indeterminate origin and myeloma].
    Bury J; Salmon J; Fillet G
    Rev Med Liege; 1988 Apr; 43(8):270-4. PubMed ID: 3285431
    [No Abstract]   [Full Text] [Related]  

  • 49. Natural interferon-alpha in combination with melphalan/prednisone versus melphalan/prednisone in the treatment of multiple myeloma stages II and III: a randomized study from the Myeloma Group of Central Sweden.
    Osterborg A; Björkholm M; Björeman M; Brenning G; Carlson K; Celsing F; Gahrton G; Grimfors G; Gyllenhammar H; Hast R
    Blood; 1993 Mar; 81(6):1428-34. PubMed ID: 8453092
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Recent biological and therapeutic advances in multiple myeloma].
    Coppetelli U; Avvisati G; Tribalto M; Cantonetti M; La Verde G; Petrucci T; Stasi R; Papa G
    Recenti Prog Med; 1992 Sep; 83(9):520-7. PubMed ID: 1439122
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Survival and therapy of multiple myeloma. Apropos of 56 observed cases].
    Locatelli F; Giovanelli E; Neretto G; Furno F; Pellerito R
    Minerva Med; 1979 Mar; 70(13):925-33. PubMed ID: 220567
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The treatment of multiple myeloma using vincristine, carmustine, melphalan, cyclophosphamide, and prednisone (VBMCP) alternating with high-dose cyclophosphamide and alpha(2)beta interferon versus VBMCP: results of a phase III Eastern Cooperative Oncology Group Study E5A93.
    Kyle RA; Jacobus S; Friedenberg WR; Slabber CF; Rajkumar SV; Greipp PR
    Cancer; 2009 May; 115(10):2155-64. PubMed ID: 19248045
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [A high serum level of interleukin-6 in a patient with aggressive multiple myeloma].
    Abe Y; Muta K; Kato S; Sadamura S; Nishimura J; Nawata H; Takeichi N; Sakai K
    Rinsho Ketsueki; 1991 Nov; 32(11):1458-62. PubMed ID: 1758053
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A review of the clinical studies of alpha-interferon in the management of multiple myeloma.
    Cooper MR
    Semin Oncol; 1991 Oct; 18(5 Suppl 7):18-29. PubMed ID: 1948125
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Interferon: a new weapon in the therapeutic strategy of multiple myeloma].
    Avvisati G; Petrucci MT; Mandelli F
    Haematologica; 1990; 75 Suppl 4():68-71. PubMed ID: 1705913
    [No Abstract]   [Full Text] [Related]  

  • 56. Standard therapy versus autologous transplantation in multiple myeloma.
    Attal M; Harousseau JL
    Hematol Oncol Clin North Am; 1997 Feb; 11(1):133-46. PubMed ID: 9081208
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Extraskeletal diffusion of multiple myeloma. A clinico-pathological description of 4 cases].
    Cantore M; Smerieri F; Bucalossi A; Leoncini L
    Recenti Prog Med; 1991 Nov; 82(11):598-602. PubMed ID: 1763233
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol.
    Case DC; Lee DJ; Clarkson BD
    Am J Med; 1977 Dec; 63(6):897-903. PubMed ID: 605911
    [No Abstract]   [Full Text] [Related]  

  • 59. [Prognosis and therapy of multiple myeloma].
    Sonntag RW
    Schweiz Med Wochenschr; 1978 Aug; 108(32):1247-51. PubMed ID: 675217
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Consolidation treatment with dexamethasone and alpha-2B recombinant interferon further reduces the M-component level in multiple myeloma patients responding to conventional induction chemotherapy.
    Palumbo AP; Garino AL; Frieri R; Gallone G; Boccadoro M; Pileri A
    Haematologica; 1990; 75(6):576-8. PubMed ID: 2098302
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.